Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Coupling reaction products of diazotized 2-amino-6-[(2-substitued ethyl)sulfonyl]naphthalene-1-substituted acid with 4-({4-chloro-6-[ethyl(3-{[2-(substituted oxy)ethyl]sulfonyl}phenyl)amino]-heteromonocycl-2-yl}amino)-5-hydroxynaphthalene-2,7-disubstituted acid and their sodium and potassium salts
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
- Repeated dose toxicity, oral: NOAEL = 300 mg/Kg bw for the rat, (OECD 407); study “Simon (2010) Repeated dose toxicity: oral”
- Repeated dose toxicity, dermal: no study available
- Repeated dose toxicity, inhalation: no study available
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 300 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
- Repeated dose toxicity, oral:
One fully reliable study is available (Simon (2010) Repeated dose toxicity: oral) conducted according to OECD TG 407 and GLP (28 d, oral gavage, doses: 100, 300 and 1000 mg/kg/ d, Wistar rats).
The following test item related findings were noted: red stained feces and red stains in multiple organs (e. g. kidneys, mesenteric lymphnodes and stomach), noted in males and females at all dose levels (100, 300 and 1000 mg/kg/day) due to dying effect.
Effects seen in whithe blood cell count (high dose) and lymphocyte (mid and high dose), but in the absence of histopathologigal changes e.g. in the spleen, bone marrow, thymus or lymphnodes and no findings in the females, this effect is considered not to be adverse. Effects revealed in the biochemical analysis (decrease in potassium and phosphorus concentrations increased total protein level in correlation with increased albumin and increased albumin/globulin ratio) were noted only in males and as there was no dose response relationship. Therefore these changes were considered not to be of adverse nature. The increase in liver weights is considered to be caused by an adaptive reaction but, in absence of further findings, e.g. pathohistological changes in the liver, not to be of adverse nature.
Changes in kidney weights in males at 1000 mg/kg/day are in correlation with macroscopic and microscopic findings (deposit of pigment) in the high dose groups of both sexes and mid dose females. The deposits of red pigment were considered to be not adverse itself, but the secondary reactions consisting of increased severity of hyaline droplets and vacuolar degeneration of tubular epithelium were deemed to be adverse.
Based on the results of this study, a no-observed-effect-level (NOEL) of FAT 40850/A TE could not be established. The no-observed-adverse-effect-level (NOAEL) was established at 300 mg/kg/day. The guidance value for classification for specific target organ toxicity category 2 in the CLP guideline is 300 mg/kg bw/d for a 28 d study and is equivalent to a LOAEL. As here 300 mg/kg bw/d represent a NOAEL and as CLP is more conservative than DSD regarding classification for repeated dose toxicity, a classification of FAT 40850/A TE for this endpoint is not necessary.
The information available from a developmental toxicity/teratogenicity study conducted according to OECD 414 (Rudragowda, BSL, 103760, 2011, RL1, chapter 7.8.2) does not disagree with this conclusion in reporting a NOAEL for both maternal toxicity and fetal toxicity of FAT 40850/B TE in Wistar rats of 1000 mg/kg bw/day.
- Repeated dose toxicity, dermal:
No study available
- Repeated dose toxicity, inhalation:
No study available
Repeated dose toxicity: via oral route - systemic effects (target organ) urogenital: kidneys
Justification for classification or non-classification
Only data for exposure via the oral route is available, therefore the proposed classification is only valid for this route.
Based on the above stated assessment of the oral repeated dose toxicity of FAT 40850/A TE (NOAEL = 300 mg/kg bw/d, 28 d rat, gavage, systemic effects in the kidneys) the substance does not need to be classified according to Council Directive 2001/59/EC (28th ATP of Directive 67/548/EEC) and according to CLP (REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL) as implementation of UN-GHS in the EU.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.